Progression in immunotherapy for advanced prostate cancer
Frontiers in Oncology · 28.02.2023 · 13
DOI: 10.3389/fonc.2023.1126752 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 28.02.2023. Verfasst von Hao Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer is one of the most common malignant cancers of the male genitourinary system and has high morbidity and mortality. Currently, treatment modalities for localized prostate cancer focus mainly on radical prostatectomy or radical radiation therapy. Some patients still experience disease recurrence or progression after these treatments, while others are already at an advanced stage or have metastases at the time of diagnosis. With the continuous development and progress of medicine in recent years, immunotherapy has become a revolutionary cancer treatment, and has achieved remarkable accomplishments in the treatment of hematologic malignancies. A variety of immunotherapies have also appeared in the field of advanced prostate cancer treatment, including therapeutic vaccines and immune checkpoint therapies. Despite the discrepancy between the results of some immunotherapy studies, immunotherapy for prostate cancer has shown some initial success, especially in combination immunotherapies. Currently, immunotherapy is mainly used in advanced prostate cancer, especially in patients with metastatic castration-resistant prostate cancer. However, with the development of more clinical trials of immunotherapy, more evidence will be provided supporting the rational application of immunotherapy in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Urology, Weifang People's Hospital, Weifang Medical University, Weifang, Shandong, China.
- Department of Immunology, School of Basic Medical sciences, Weifang Medical University, Weifang, Shandong, China.
Zitieren
APA
Liang, H., Liu, Y., Guo, J., Dou, M., Zhang, X., Hu, L., & Chen, J. (2023). Progression in immunotherapy for advanced prostate cancer. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1126752
Vancouver
Liang H, Liu Y, Guo J, Dou M, Zhang X, Hu L, et al. Progression in immunotherapy for advanced prostate cancer. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1126752
BibTeX
@article{Liang2023,
author = {Liang, Hao and Liu, Yang and Guo, Jiao and Dou, Maoyang and Zhang, Xiaoyi and Hu, Liyong and Chen, Jun},
title = {Progression in immunotherapy for advanced prostate cancer},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1126752}
}
EUVIMED